However, tumors can escape immune attack by various mechanisms of immunosuppression [7, 8].A small number of genes, such as programmed cell death 1 ligand 1 (PD-L1), that enable tumors to evade the immune system have been the focus of intense clinical development efforts [9–11].Reactivating the antitumor responses of T cells by checkpoint blockade has recently been demonstrated to have notable effects on treating cancer, but its response rate needs to be further improved [12, 13]. The gene discussed is CD274; the disease is cancer.